Drugs / SYHX1903
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05055791 | Dec 2021 → Jun 2026 overdue | acute myeloid leukemia, plasma cell myeloma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-05-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE CDK9 INHIBITOR "SYHX1903" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗
The board of directors (the “ Board”) of CSPC Pharmaceutical Group Limited (the “ Company ”, together with its subsidiaries, the “Group”) is pleased to announce that “SYHX1903” (the “Product ”), independently developed by the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-05-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE CDK9 INHIBITOR "SYHX1903" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHX1903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05055791 ↗ |
| Route | Oral | “orally” NCT05055791 ↗ |